HCV genotype identification and characterization of NS5B resistance-associated substitutions (RASs) occurring as natural polymorphisms are crucial for establishing the treatment outcome and duration and which patients may benefit from treatment with direct acting antivirals (DAAs), sofosbuvir and dasabuvir.